ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BDSX
TLSI (30) XGN (36) YDES (44) BNR (20) ⌘ Pro Terminal →

Biodesix Inc. (BDSX) — RQD Stock Rating Cockpit

$21.78 -6.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.49

Biodesix Inc. (BDSX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $245.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BDSX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BDSX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Biodesix Inc. (NASDAQ: BDSX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $21.78 (-6.34% 1D, market cap $245.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BDSX ranks #462 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BDSX compare to TLSI and XGN in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), BDSX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $227.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, BDSX leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BDSX?
▼

Per BDSX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439725), Biodesix Inc. generated $88.5M in revenue (+24.1% YoY), -$35.3M in net income, and -$23.5M in free cash flow against $87.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $21.49 (-1.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (9)Whales (8)SEC (11)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$34 Bull$20 Base$16 Bear
📬 FREE BDSX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDSX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY BDSX SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$25.00-4.5% Next Q
Q2 (-2Q)
45
Grade D$23.87-8% Next Q
Q3 (-1Q)
43
Grade D$21.95-0.8% Next Q
Current
40
Grade D-$21.78-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BDSX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BDSX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.38) and Max Pain ($22.87) forces dealer call-delta covering toward $33.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDSX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BDSX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
44.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE62% OF RANGE
L: $5$21.78H: $32
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BDSX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -9.02% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

11/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like BDSX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BDSX)

  • ✓Walkthrough of BDSX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BDSX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +93.26%🛡️ HOLDING TREND SUPPORT
2026-11-03O $24.72H $24.72L $21.78C $21.78VOL 67.3K
RES: $39.17SUP: $20.19SMA50: $26.38SMA200: $18.83
$33.53$27.06$20.60$14.13$7.66RES $39.17SUP $20.19$21.782026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDSX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDSX Butterfly Map → + Track BDSX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +24.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BDSX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDSX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BDSX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDSX)

Health Care Rank #462 of 1015 ⚔️ TLSI vs BDSX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDSX vs. TLSI, XGN, YDES, BNR)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Biodesix Inc. (BDSX) ranks #462 by composite RQD confidence (40/100, grade D-) and #544 by equity capitalization ($245.4M). Within this direct 5-issuer industry benchmark cohort, BDSX leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with BDSX at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BDSX ACTIVE
Biodesix Inc.
D- 40/100 — — -35.0% -6.34% $245.4M Benchmark Subject
TLSI
TriSalus Life Sciences Inc.
E 30/100 — 84.6% -35.0% -1.89% $227.8M /tlsi-vs-bdsx →
XGN
Exagen Inc.
D- 36/100 — 58.3% -35.0% -2.33% $208.1M /xgn-vs-bdsx →
YDES
YD Bio Limited
D 44/100 — 28.1% -20.0% +0.51% $420.7M /ydes-vs-bdsx →
BNR
Burning Rock Biotech Limited
E 20/100 — 74.7% -35.0% -7.89% $115.0M /bnr-vs-bdsx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001439725 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biodesix Inc. (BDSX) reported GAAP revenue of $88.5M (+24.1% vs. FY2024 revenue of $71.3M , and +80.3% cumulative change since FY2023) , GAAP net income of -$35.3M, operating cash flow of -$23.3M, and free cash flow of -$23.5M (+54.6% YoY). On the balance sheet, BDSX closed FY2025 with $87.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $88.5M -$35.3M -$23.3M -$23.5M $87.5M —
FY2024 (FY) 2024-12-31 $71.3M -$42.9M -$48.6M -$51.9M $97.2M —
FY2023 (FY) 2023-12-31 $49.1M -$52.1M -$22.9M -$22.9M — —

3. BDSX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDSX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Biodesix Inc. (NASDAQ: BDSX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $21.78 (-6.34% 1D, market cap $245.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BDSX ranks #462 in composite RQD confidence.

How does BDSX compare to TLSI and XGN in the Health Care sector?

Within the Health Care sector (Medical Specialities), BDSX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $227.8M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, BDSX leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BDSX?

Per BDSX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439725), Biodesix Inc. generated $88.5M in revenue (+24.1% YoY), -$35.3M in net income, and -$23.5M in free cash flow against $87.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BDSX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDSX last traded at $21.78 (-6.34% on volume of 75,651 shares), positioning the stock -17.44% below its 50-day simple moving average ($26.38) and +15.67% above its 200-day simple moving average ($18.83). Across its 52-week range of $5.26 to $31.97, BDSX sits at the 61.8% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.06 to $24.50).

Direct Sub-Reports: BDSX RQD Cockpit BDSX 12M Forecast BDSX Earnings & Move BDSX Dividends & DRIP BDSX Insiders & 13F BDSX Whale Options BDSX Profit Sankey BDSX News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BDSX — Biodesix Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Biodesix Inc. (BDSX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $21.78 (-6.34% 1D, market capitalization $245.4M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -31.5%, and free cash flow yield of -9.02%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Biodesix Inc. (BDSX) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical Specialities industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Biodesix Inc. (BDSX) reported $88.5M in annual revenue (up from $71.3M in FY2024, +24.1% YoY) and -$35.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($49.1M revenue, -$52.1M net income) through FY2025, BDSX scaled operating cash flow to -$23.3M and free cash flow to -$23.5M, backed by $87.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.02% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $5.26 – $31.97 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -31.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), BDSX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BDSX sustain or expand its -31.5% operating margin and -35.0% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $88.5M and free cash flow of -$23.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BDSX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BDSX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Biodesix Inc. (BDSX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BDSX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BDSX Bull vs. Bear Conversation Board — What's Your Call at $21.78?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BDSX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BDSX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $29.08 (+25.0%)
📌 Pinned Debate

Revenue grew from $49.1M in FY 2023 to $88.5M in FY 2025 while operating losses narrowed from -$41.3M to -$27.9M.

Don't sleep on BDSX's setup in Health Care. Revenue grew from $49.1M in FY 2023 to $88.5M in FY 2025 while operating losses narrowed from -$41.3M to -$27.9M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (40/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@MultipleCompression Shorting a 8/20 institutional whale-flow stock at $23.26 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $19.54 (-16.0%)
Spot @ $23.26

ROIC of -35% and FCF yield of -9.02% indicate the business is not yet generating returns for owners.

I respect the product at Biodesix Inc., but the stock at $23.26 is a different story. ROIC of -35% and FCF yield of -9.02% indicate the business is not yet generating returns for owners.. FCF yield is -9.02% and RQD sits at 40/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%